<DOC>
	<DOCNO>NCT02768415</DOCNO>
	<brief_summary>Apatinib orally administer second-generation blocker phosphorylation tyrosine residue within intracellular domain VEGF receptor 2 ( VEGFR2 ) . A prospective , open label , phase II multicenter trial apatinib heavily pretreated patient metastatic triple-negative breast cancer demonstrate daily dose apatinib 500 mg/day active pretreated metastatic TNBC encouraging rate disease stabilization PFS . Vinorelbine highly active drug treatment MBC , single agent combination regimen , well tolerate , low incidence severe toxicity . Clinical trial demonstrate oral NVB provide comparable effectiveness iv NVB . oral availability allow use different schedule . The NCCN guideline introduces combination chemotherapy one standard treatment option metastatic breast cancer , especially patient visceral metastasis and/or need rapid symptom disease control . Theoretically , anti-angiogenesis regimen combine chemotherapy may present increase therapeutic effect . Related research urgently need find optimal combine therapy .</brief_summary>
	<brief_title>Study Apatinib Combined With Oral Vinorelbine Metastatic HER2 Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Age 18 75 yearold woman ; HER2 negative ( immunohistochemistry fluorescence situ hybridization ) ; 2 . ECOG score : 01 , expect survival time ≥ 3months ; 3 . Pathologically cytologically confirm breast cancer ; 4 . Anthracycline / taxane pretreated ( adjuvant , neoadjuvant ) breast cancer patient fail 12 standard chemotherapy recurrence metastasis ; 5 . According RECIST 1.1 , exist least ≥1 measurable lesion ( CT ＞1cm，other examination ＞2cm ) ; 6 . The patient enough organ function . The laboratory test index must comply follow requirement : Blood routine : neutrophil≥1.5G/L , platelet count ≥80G/L , hemoglobin ≥90g/L Liver function : serum bilirubin ≤ 1.5 time upper limit normal value ; ALT AST≤2.5 time upper limit normal value ; ALT AST≤5 time upper limit normal value liver metastasis Renal function : serum creatinine ≤ 1.0times upper limit normal value , creatinine clearance ＞50ml/min（CockcroftGault formula ) 7 . Women childbearing age carry pregnancy test ( serum urine ) within 7 day recruit , result negative ; willing adopt appropriate method contraception trial 8 week last administration； 8 . Can swallow oral drug ; 9 . The patient good compliance therapy followup schedule able understand study protocol sign Informed Consent Form . 1 . The patient pregnancy lactation growth period take effective contraception ; 2 . The patient receive ≥3 chemotherapies（Do include endocrine therapy）after recurrence metastasis ; involve clinical trial four week prior start study ; 3 . The patient variety factor affect oral administration absorption drugs； 4 . The patient previously receive antiVEFG antiVEGFR therapies； 5 . The patient rapid progression viscera invasion ( liver lesion ＞1/2 viscera area liver dysfunction ) ; 6 . The patient uncontrollable mental illness . 7 . The patient serious adverse effect oral vinorelbine allergic vinorelbine . 8 . The patient bone metastasis without measurable lesion ; 9 . The patient experience severe cardiovascular disease ; 10 . The patient experience severe upper gastrointestinal ulcer malabsorption syndrome . 11 . Abnormal bone marrow function ( neutrophil＜1.5G/L , platelet count ＜75G/L , hemoglobin ＜90g/L ) ； 12 . Abnormal renal function ( serum creatinine ＞ 1.5 time upper limit normal value ) ； 13 . Abnormal liver function ( serum bilirubin ≤ 1.5 time upper limit normal value ) ; 14 . The patient uncontrollable brain metastasis ; 15 . The patient good compliance therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>